Zacks Research Forecasts Higher Earnings for Zimmer Biomet

Key Points

• Analysts at Zacks Research have raised their earnings estimate for Zimmer Biomet in Q3 2025 from $1.78 to $1.87 per share, with a full-year earnings consensus now at $8.22 per share.
• Zimmer Biomet reported earnings of $2.07 per share for its latest quarter, exceeding analysts' expectations of $1.98, and showed a year-over-year revenue increase of 7.0%.
• The company recently announced a quarterly dividend of $0.24 per share, which is set to be paid on October 31st, reflecting a 0.9% dividend yield.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Investment analysts at Zacks Research lifted their Q3 2025 earnings estimates for shares of Zimmer Biomet in a research note issued to investors on Thursday, August 28th. Zacks Research analyst Team now anticipates that the medical equipment provider will earn $1.87 per share for the quarter, up from their prior forecast of $1.78. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet's Q4 2025 earnings at $2.36 EPS, Q1 2026 earnings at $1.88 EPS, Q2 2026 earnings at $2.11 EPS, Q3 2026 earnings at $2.05 EPS, Q1 2027 earnings at $2.11 EPS, Q2 2027 earnings at $2.23 EPS and FY2027 earnings at $8.71 EPS.

ZBH has been the subject of several other reports. Wells Fargo & Company lowered their target price on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Morgan Stanley lowered their target price on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Royal Bank Of Canada raised their target price on shares of Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Truist Financial set a $101.00 target price on shares of Zimmer Biomet in a report on Tuesday, May 6th. Finally, Roth Capital reaffirmed a "buy" rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Nine analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and an average target price of $111.44.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $106.11 on Monday. Zimmer Biomet has a fifty-two week low of $89.22 and a fifty-two week high of $116.71. The stock has a market capitalization of $21.02 billion, a price-to-earnings ratio of 25.82, a PEG ratio of 2.09 and a beta of 0.68. The business has a 50-day moving average of $97.09 and a 200-day moving average of $99.47. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. The firm had revenue of $2.08 billion during the quarter, compared to analysts' expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company's revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet's payout ratio is 23.36%.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the transaction, the insider owned 20,424 shares in the company, valued at $1,940,280. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.70% of the company's stock.

Institutional Investors Weigh In On Zimmer Biomet

Several hedge funds and other institutional investors have recently bought and sold shares of ZBH. Ameriprise Financial Inc. increased its position in shares of Zimmer Biomet by 236.0% during the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock worth $517,039,000 after acquiring an additional 3,208,596 shares in the last quarter. Dodge & Cox grew its position in Zimmer Biomet by 12.9% in the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider's stock worth $2,015,510,000 after purchasing an additional 2,533,009 shares in the last quarter. Norges Bank bought a new stake in Zimmer Biomet in the 2nd quarter worth about $225,867,000. JPMorgan Chase & Co. grew its position in Zimmer Biomet by 251.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock worth $235,571,000 after purchasing an additional 1,488,918 shares in the last quarter. Finally, Nuveen LLC bought a new stake in Zimmer Biomet in the 1st quarter worth about $155,891,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.